King's College London

Research portal

Advances in medical management of acute liver failure in children: promoting native liver survival

Research output: Contribution to journalReview articlepeer-review

Akash Deep, Emma C. Alexander, Yonca Bulut, Emer Fitzpatrick, Serge Grazioli, Nigel Heaton, Anil Dhawan

Original languageEnglish
Pages (from-to)725-737
Number of pages13
JournalThe Lancet Child and Adolescent Health
Volume6
Issue number10
DOIs
E-pub ahead of print14 Sep 2022

Bibliographical note

Funding Information: AkD is Chair of Scientific Affairs of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) and Chair of the Working Group for Liver Failure in ESPNIC. AnD is a recipient of a National Institute for Health Research i4i grant to develop treatment for ALF with alginate microbead embedded hepatocytes and a Medical Research Council (MRC) grant for a first in human clinical trial of alginate embedded human hepatocytes as treatment for ALF (MRC MR/V038583/1); has been paid by Ambys and Johnson & Johnson for consultation; has a patent pending approval for alginate microbead manufacturing, and is part of the European Society for Paediatric Gastroenterology Hepatology and Nutrition. ALF guideline group. EF is in receipt of an MRC grant (MRC MR/V038583/1) for the research of hepatocyte transplantation; and has received payment for organising a Falk Symposium (unconnected). All other authors declare no competing interests. Publisher Copyright: © 2022 Elsevier Ltd

King's Authors

Abstract

Paediatric acute liver failure (PALF) is defined as a biochemical evidence of acute liver injury in a child with no previous history of chronic liver disease characterised by an international normalised ratio (INR) of 1·5 or more unresponsive to vitamin K with encephalopathy, or INR of 2·0 or more with or without encephalopathy. PALF can rapidly progress to multiorgan dysfunction or failure. Although the transplant era has substantially changed the outlook for these patients, transplantation itself is not without risks, including those associated with life-long immunosuppression. Consequently, there has been an increased focus on improving medical management to prioritise bridging of patients to native liver survival, which is possible due to improved understanding of the underlying pathophysiology of multiorgan involvement in PALF. In this Review, we discuss recent advances in the medical management of PALF with an aim of reducing the need for liver transplantation. The Review will focus on the non-specific immune-mediated inflammatory response, extracorporeal support devices, neuromonitoring and neuroprotection, and emerging cellular and novel future therapeutic options.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454